Navigation Links
Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Date:1/7/2011

s, including the more than 130 Emergency INDs requested by leading investigators," said Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix.  "The demand for CMX001 to treat life-threatening infections continues to grow among the clinical community, and we are extremely proud to provide CMX001 under this open-label study."

CMX001-350 Open-Label Study Design

The primary objective of the multicenter open-label study of CMX001 is to provide CMX001 to patients with immediately life-threatening or serious disease caused by any of 12 different viral infections resulting from dsDNA viruses. The open-label study is expected to enroll 200 infected adult and pediatric patients.  Critically-ill patients expected to enroll in this study in the highest numbers include immunocompromised patients suffering from a variety of dsDNA infections, particularly patients undergoing solid organ transplant or hematopoietic stem cell transplant.  However, the study is intended for any patient with a serious dsDNA viral disease for whom no satisfactory alternate therapy is available and who does not qualify for other CMX001 clinical studies.(1)

The study will evaluate the safety, tolerability and antiviral activity of CMX001.  Researchers will also evaluate the activity of CMX001 through changes in clinical signs and symptoms of infection.  Patients will receive CMX001 orally twice weekly for up to three months, and treatment may be extended for up to six months depending on the patient's clinical response.  Antiviral activity will be measured by changes in viral burden from baseline in an individual patient's condition and across all patients with a given dsDNA virus.  Drug pharmacokinetics and any potential signs of drug resistance will also be assessed.

The clinical design parameters of the CMX001-350 study were based in large part on Chimerix's experiences providing CMX001 to patients under investigator-held
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... , , , , ... i c , Inc. (Nasdaq: ... medical imaging systems and surgical products dedicated to serving the healthcare needs ... study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic ...
... VIENNA, Va., Aug. 18 CEL-SCI Corporation (NYSE Amex: ... of its work towards creating a novel treatment and vaccination against ... in which the virus has acquired greater morbidity and mortality. ... are highly conserved and essential for the virus, survival. This ...
Cached Medicine Technology:Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 2Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 3Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth 4CEL-SCI Expands H1N1 Flu Virus Work 2CEL-SCI Expands H1N1 Flu Virus Work 3
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic USA vs. ... will face the Australia Women's National Team in conjunction with their Victory Tour to celebrate ... Carli Lloyd from the USA team was awarded the Golden Ball as the best player ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a ... , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare dedicated ... a service (SaaS). , HITaaS manages all aspects of infrastructure, security, ...
(Date:7/31/2015)... York (PRWEB) , ... July 31, 2015 , ... Physical therapy for ... limits the patient's quality of life. It keeps the patient from doing what they want ... and may have a hard time using the stairs. The patient's exercise regime may be ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers invites the public to ... August 15th, 2015 from 9am – 12pm. Timber frame raisings are special, ... entire community as the culmination of months of effort, planning, fundraising, and dreaming takes ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... * concentrated Tylenol(R) Infants, Drops Plus ... * PediaCare(R) ... Consumer,Healthcare, a division of McNeil-PPC, Inc., announced today that the,company is ... used as directed, these medicines are generally,recognized as safe and effective. ...
... 11 ALOKA Co., Ltd., a pioneer in ... of Masanobu Tada as President, and Carlos Faustmann ... AG, the company,s,wholly-owned European headquarters in Zug, Switzerland, ... the Global Marketing of the company as,general manager ...
... Passage of Plan to Give Access to Affordable Health ... week after Cover,All Pennsylvanians, the centerpiece of his "Prescription ... Rendell today held a,town meeting in Erie as part ... will highlight the need to lower health care costs,and ...
... virus (MMTV) - which causes mammary cancer in mice - ... week shows. The study, published in the online open access ... be involved in causing human breast cancer. , The idea ... around for over 50 years. In the 1990s, researchers detected ...
... Avicena Group,Inc. (OTC Bulletin Board: AVGO), a late-stage ... neurodegenerative,disorders, announced today the appointment of its C.E.O., ... of the Company,s,Board of the Directors. Dr. Tsao- ... Board to focus his time on other business,ventures. ...
... 10 HealthShares(TM) Inc., an investment,company with a family ... has approved the transfer of its 19 currently NYSE-listed,HealthShares ... accordance with NYSE Euronext requirement to transfer of all ... expected to be completed prior to,October 31, 2007. The ...
Cached Medicine News:Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:ALOKA Appoints New Management in Europe 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 3Health News:Mouse mammary tumor virus can replicate in human cells 2Health News:Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors 2Health News:XShares Group LLC to Begin the Transfer of HealthShares(TM) NYSE-Listed ETFs to NYSE Arca 2Health News:XShares Group LLC to Begin the Transfer of HealthShares(TM) NYSE-Listed ETFs to NYSE Arca 3Health News:XShares Group LLC to Begin the Transfer of HealthShares(TM) NYSE-Listed ETFs to NYSE Arca 4
For the quantitative in vitro determination of Microalbumin in human urine....
Determination of Reptilase Time.Extracted venom of Bothrops atrox. 20 BU (Batroxobin unit) per vial....
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: